Stories by David Sherman

As a professor at Seattle Biomedical Research Institute (Seattle BioMed), David Sherman studies the virulence and latency of Myocbacterium tuberculosis, and is also engaged in developing novel drugs directed against this tenacious pathogen. He began work on M. tuberculosis while working at a biotech firm, where he played a lead role in the discovery and early development of the anti-TB agent PA-824 that is now in clinical trials. He earned his Ph.D. in Biochemistry from Vanderbilt University, and performed post-graduate work at the Rockefeller University and at Washington University in St. Louis. Sherman's current projects include a detailed analysis of the M. tuberculosis gene regulatory network in vitro and in vivo, and the pursuit of latency-relevant drug targets. His laboratory routinely employs a variety of research tools, including molecular genetics, systems biology, biochemistry, cultivation in vitro and in vivo, and whole genome microarray analysis.